Citigroup Cuts Acumen Pharmaceuticals Price Target to $1 From $5
Citigroup cut its price target on Acumen Pharmaceuticals and lowered its rating to Neutral from Buy.
Citigroup cut its price target on Acumen Pharmaceuticals and lowered its rating to Neutral from Buy.